Literature DB >> 17653964

The NAD(P)H oxidase inhibitor apocynin improves endothelial NO/superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: comparison to calcium channel blockade.

Anselm T Bäumer1, Christian A Krüger, Juliane Falkenberg, Henrik Ten Freyhaus, Renate Rösen, Klaus Fink, Stephan Rosenkranz.   

Abstract

The vascular NAD(P)H oxidase contributes to endothelial dysfunction and high blood pressure in the spontaneously hypertensive rat by enhancing superoxide production. We investigated the effects of apocynin, a NAD(P)H oxidase inhibitor, on blood pressure and vascular radical and nitric oxide formation in SHR and compared its effects to the calcium channel blocker nifedipine. Apocynin (over four weeks) lowered systolic blood pressure significantly and as effectively as nifedipine. Both apocynin and nifedipine significantly reduced superoxide production. In parallel, vascular nitric oxide production and ecNOS activity was significantly increased by apocynin treatment. Therefore, apocynin may be an effective antihypertensive drug in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653964     DOI: 10.1080/10641960701500398

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  11 in total

1.  Radiation nephropathy is not mitigated by antagonists of oxidative stress.

Authors:  Eric P Cohen; Brian L Fish; Amy A Irving; Mohan M Rajapurkar; Sudhir V Shah; John E Moulder
Journal:  Radiat Res       Date:  2009-08       Impact factor: 2.841

2.  Enhanced vascular PI3K/Akt-NOX signaling underlies the peripheral NMDAR-mediated pressor response in conscious rats.

Authors:  Marie A McGee; Abdel A Abdel-Rahman
Journal:  J Cardiovasc Pharmacol       Date:  2014-05       Impact factor: 3.105

3.  Apocynin improves oxygenation and increases eNOS in persistent pulmonary hypertension of the newborn.

Authors:  Stephen Wedgwood; Satyan Lakshminrusimha; Kathryn N Farrow; Lyubov Czech; Sylvia F Gugino; Fernando Soares; James A Russell; Robin H Steinhorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-23       Impact factor: 5.464

4.  Apocynin improves endothelial function and prevents the development of hypertension in fructose fed rat.

Authors:  Banappa S Unger; Basangouda M Patil
Journal:  Indian J Pharmacol       Date:  2009-10       Impact factor: 1.200

5.  Increased superoxide levels in ganglia and sympathoexcitation are involved in sarafotoxin 6c-induced hypertension.

Authors:  Melissa Li; Xiaoling Dai; Stephanie Watts; David Kreulen; Gregory Fink
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-09-03       Impact factor: 3.619

6.  Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice.

Authors:  Yu-qiong Li; Xiao-bo Li; Shu-jie Guo; Shao-li Chu; Ping-jin Gao; Ding-liang Zhu; Wen-quan Niu; Nan Jia
Journal:  Acta Pharmacol Sin       Date:  2013-01-21       Impact factor: 6.150

7.  Impaired vascular KATP function attenuates exercise capacity in obese zucker rats.

Authors:  Silu Lu; Lusha Xiang; John S Clemmer; Andrew R Gowdey; Peter N Mittwede; Robert L Hester
Journal:  Microcirculation       Date:  2013-10       Impact factor: 2.628

Review 8.  NADPH oxidases in vascular pathology.

Authors:  Anna Konior; Agata Schramm; Marta Czesnikiewicz-Guzik; Tomasz J Guzik
Journal:  Antioxid Redox Signal       Date:  2013-11-01       Impact factor: 8.401

9.  Apocynin and ebselen reduce influenza A virus-induced lung inflammation in cigarette smoke-exposed mice.

Authors:  L C Oostwoud; P Gunasinghe; H J Seow; J M Ye; S Selemidis; S Bozinovski; R Vlahos
Journal:  Sci Rep       Date:  2016-02-15       Impact factor: 4.379

10.  Hydrogen Sulfide Improves Endothelial Dysfunction via Downregulating BMP4/COX-2 Pathway in Rats with Hypertension.

Authors:  Lin Xiao; Jing-Hui Dong; Sheng Jin; Hong-Mei Xue; Qi Guo; Xu Teng; Yu-Ming Wu
Journal:  Oxid Med Cell Longev       Date:  2016-08-23       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.